# Cancer Biology and Signaling

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2023 · $31,940

## Abstract

CANCER BIOLOGY AND SIGNALING ABSTRACT
The overarching goal of the Cancer Biology and Signaling Program (CBS) is to provide fundamental scientific
knowledge for the molecular and cellular basis of cancer (including initiation, progression, and metastasis) and
the interaction between cancer and the immune system. Scientific discoveries of CBS members are aimed to
provide molecular targets for cancer detection, diagnosis, and therapy through 2 aims: 1) understand signaling
pathways involved in cell growth regulation; 2) investigate the molecular mechanisms of oncogenic development
and progression. For these goals, research conducted by CBS members during the current project period has
made a number of major advancements on signaling pathways in cell growth control, mechanisms of oncogenes
and tumor suppressors in oncogenesis, and interaction between cancer and host immune system. The central
themes of CBS include 1) signal transduction and 2) cell growth, with a developing focus on immunity in
tumorigenesis. Drs. Dong-Er Zhang and Kun-Liang Guan have been CBS co-leaders since 2008. They have
complementary expertise (alteration of transcription of liquid cancer development and signal transduction
regulating growth of solid cancer cells) and share a common vision for future success of CBS, which will continue
to advance basic knowledge and provide the scientific basis for early cancer prevention, detection, and
treatment. The 52 members of CBS represent 11 departments and 3 schools. In 2017, CBS members had
$18.6M in cancer-relevant, peer-reviewed funding (direct costs), of which $8.3M (45%) was from NCI, $9.1M
(49%) was from other NIH sources, and $1.1M (6%) was from other peer-reviewed agencies. In addition, CBS
members had $1.6M in cancer-relevant, non-peer reviewed funding (direct costs) During the project period
(2013-2017), members authored 669 cancer-relevant publications, of which 78 (12%) were intra-programmatic,
162 (24%) were inter-programmatic, and 190 (28%) were collaborative with investigators from other NCI-
designated cancer centers.

## Key facts

- **NIH application ID:** 10666385
- **Project number:** 5P30CA023100-37
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** DONG-ER ZHANG
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $31,940
- **Award type:** 5
- **Project period:** 1996-07-01 → 2026-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10666385

## Citation

> US National Institutes of Health, RePORTER application 10666385, Cancer Biology and Signaling (5P30CA023100-37). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10666385. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
